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Abstract  
Cognitive deficits are a core feature of schizophrenia. There is ongoing debate about 
whether cognition is affected by antipsychotic drugs (APDs). This study examined the 
effect of long-term treatment with APDs on cognition in schizophrenia. Cognitive 
function was assessed in 418 patients with schizophrenia on long-term treatment with 
APDs (215 on clozapine, 91 on risperidone, and 112 on typical APDs) and 159 healthy 
controls using the Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS). Schizophrenia symptomatology was assessed using the Positive and 
Negative Syndrome Scale (PANSS). We found that cognitive test scores were 
significantly lower in all patient subjects compared to healthy controls on almost all of 
the total and subscores of RBANS (all p<0.001) except for the 
visuospatial/constructional index. Individuals taking clozapine showed worse 
immediate and delayed memory performance than those taking typical APDs (all 
p<0.01). Moreover, individuals taking clozapine showed better language performance 
than those taking risperidone (p<0.01). Immediate memory and delayed memory were 
modestly correlated with the types of APDs and the PANSS negative scores. Our results 
show that individuals taking clozapine performed worse in immediate and delayed 
memory than those taking typical APDs, but exemplified better language performance 
than those taking risperidone.  
 
Keywords: Schizophrenia, Cognitive deficits, Antipsychotic drugs, Treatment 
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Introduction 
Cognition in schizophrenia is impaired across multiple domains, including memory, 
attention, processing speed, and executive function (Keefe and Harvey, 2012; Vyas et 
al., 2011). Cognitive impairment in schizophrenia is directly related to socio-vocational 
function, which can have a greater adverse effect on brain function than the positive or 
negative symptoms of schizophrenia (Velligan et al., 2000). Cognitive impairment 
significantly affects the acquisition of new skills, limits or prevents employment, and 
seriously reduces patients’ quality of life (Sidlova et al., 2011; Tomida et al., 2010). 
Currently, the pathophysiological mechanism of cognitive deficits in patients with 
schizophrenia is unclear. Antipsychotic drugs (APDs) are usually prescribed to treat 
schizophrenia. However, the effects of APDs on cognitive deficits remain controversial 
for patients with schizophrenia on long-term medication (Daban et al., 2005; Keefe and 
Harvey, 2012; Thornton et al., 2006; Woodward et al., 2005).  
 
Previous studies have shown that cognitive function in patients with schizophrenia 
could be influenced by APDs (Beninger et al., 2010; Terry and Mahadik, 2007). For 
example, some studies have suggested that APDs induce distinct regionalized neural 
responses in different brain regions that are associated with distinct cognitive functions 
(Beninger et al., 2010; Westerink, 2002). Moreover, some studies have shown that 
APDs, in particular atypical APDs, are associated with the improvement in some 
cognitive deficits in patients with schizophrenia, especially executive function, spatial 
memory, processing speed, and attention (Hill et al., 2010; Keefe et al., 2006; Meltzer 
and McGurk, 1999; Woodward et al., 2005). Furthermore, a meta-analytic study 
supported that the inherent anticholinergic property of APDs may affect long-term 
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memory in patients with schizophrenia (Thornton et al., 2006). An animal study also 
indicated that APDs had a negative effect on cognition, especially for long-term 
administrations (Terry and Mahadik, 2007). However, some studies did not find that 
APDs had a major effect on cognition in patients with schizophrenia (Daban et al., 
2005; Lindenmayer et al., 1998). In addition, a few studies investigating the effects of 
APD treatments on language and immediate and delayed memory in patients with 
schizophrenia were inconclusive (Meltzer and McGurk, 1999; Minzenberg et al., 2004; 
Takeuchi et al., 2013). Thus, whether APDs affect cognition in patients with chronic 
schizophrenia, especially language and immediate and delayed memory, deserves 
further investigation.       
 
A few studies have investigated the effects of clozapine on cognition in patients with 
schizophrenia, and have shown a mixture of beneficial, deleterious or absent effects 
(Hoff et al., 1996; Lindenmayer et al., 1998; Sharma et al., 2003; Thornton et al., 2006). 
A growing body of evidence suggests that the inherent anticholinergic properties of 
some APDs might limit gains or impair memory-related task performance, as well as 
alter central cholinergic function (Minzenberg et al., 2004; Terry and Mahadik, 2007; 
Thornton et al., 2006). A radioligand binding study has shown that clozapine has the 
highest affinity for all muscarinic M1-5 receptors compared to other APDs, with the 
highest affinity for the M1 receptor (Bymaster et al., 2003). Although clozapine was 
found to have a weak partial agonist activity at the muscarinic M1 and M4 receptors, 
particularly the M4 receptors, both in vitro and in vivo studies have indicated that 
clozapine functions as an antagonist at the muscarinic M1 and M4 receptors (Bymaster et 
al., 2003). Therefore, it is important to understand whether clozapine has a specific 
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impairment effect on cognition compared to other APDs in patients with schizophrenia 
during long-term medication, especially in relation to memory-related task performance.  
 
Although risperidone is an atypical APD, it has a higher affinity and longer dissociation 
latency period for the D2 receptors than other atypical APDs such as clozapine (Kapur 
and Seeman, 2001). These properties may contribute to risperidone’s some similar 
effects to typical APDs in treating patients with schizophrenia (Houthoofd et al., 2008). 
Unlike clozapine, risperidone does not have a significant affinity with the muscarinic 
M1-5 receptors (DeLeon et al., 2004). Risperidone has been associated with improved 
and clozapine with worsened memory performance in patients with schizophrenia 
(Houthoofd et al., 2008). Another study has shown that clozapine improved language 
more than risperidone (Meltzer and McGurk, 1999). However, some studies have not 
supported the improvement effects of clozapine on language and risperidone on 
memory (Buchanan et al., 1994; Stip and Lussier, 1996). Thus the effects of risperidone 
and clozapine on cognitive function in patients with schizophrenia deserve further 
investigation, especially in relation to memory and language.  
 
In addition, compared to risperidone and typical APDs, clozapine has also been 
associated with substantial weight gain, increased serum triglyceride levels, and an 
increased risk of diabetes (Flanagan, 2008; Nasrallah, 2003). This may independently 
augment the risk of cognitive deficits. Therefore, it is important to understand the 
differences of cognitive deficits in patients with chronic schizophrenia during long-term 
clozapine, risperidone, and typical APDs treatment.  
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This study aimed to investigate whether: (1) individuals taking different APDs for 
chronic schizophrenia presented different cognitive deficits during long-term 
medication; (2) individuals taking clozapine showed worse memory performance than 
risperidone or other typical APDs; (3) individuals taking clozapine indicated better 
language performance than risperidone or other typical APDs.  
           
Methods 
Participants 
A total of 418 patients with chronic schizophrenia were recruited using a cross-sectional 
design in Beijing Hui-Long-Guan Hospital, a Beijing City owned psychiatric hospital. 
The diagnosis for each patient was made by two independent and experienced 
psychiatrists and confirmed by the Structured Clinical Interview for DSM-IV (SCID). 
All patients were aged between 25 and 70 years, diagnosed with schizophrenia for at 
least 5 years, and were on stable doses of oral APDs for at least 6 months prior to entry 
into the study. The antipsychotic treatments for the patients were given by their 
psychiatrist. The treatments were not changed when they were recruited. Antipsychotic 
treatment consisted mainly of monotherapy with clozapine (n=215), risperidone (n=91), 
and typical APDs (n=112), including haloperidol (n=28), chlorpromazine (n=32), 
perphenazine (n=24), and sulpiride (n=28). “The mean dose of each antipsychotic drug 
used in the study were 365.3±168.3 mg/day (200-700 mg/day) for clozapine, 4.9±1.4 
mg/day (2-7mg/day) for risperidone, 22±15 mg/day (4-40 mg/day) for haloperidol, 
367±163 mg/day (150-700 mg/day) for chlorpromazine, 24±17 mg/day (10-40 mg/day) 
for perphenazine and 538±266 mg/day (200-1100 mg/day) for sulpiride. The detailed 
doses for chlorpromazine equivalents for each drug were presented in Table 2”. The 
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mean antipsychotic dose was converted to approximate daily mean chlorpromazine 
milligram equivalents for each patient using standard guidelines (Woods, 2003). 
Patients were hospitalized for an average of 10.7±8.5 years.   
 
One hundred and fifty nine healthy controls were recruited during the same period from 
the Beijing community. Psychiatric disorders in the healthy controls were ruled out with 
a psychiatric interview conducted by a psychiatrist.  
 
We obtained a complete medical history, physical examination, and laboratory tests 
from all subjects. All healthy controls were in good physical health. All patients were 
free from other physical diseases, including diseases of the central nervous system, 
stroke, tumours, Parkinson’s disease, Huntington’s disease, seizure disorders, history of 
brain trauma, and acute and chronic infections. Neither patients nor healthy controls 
suffered from drug or alcohol abuse/dependence. Any subjects with a diagnosis of 
dementia or mild cognitive impairment (MCI) were excluded. The subjects were all 
from the Han Chinese population. All patients gave signed, informed consent to 
participate in the study, which was approved by the Institutional Review Board of the 
Beijing Hui-Long-Guan Hospital. 
 
Clinical assessment 
Four experienced psychiatrists, who were blind to the clinical status of patients, 
assessed the severity of the patients’ psychopathology using the Positive and Negative 
Syndrome Scale (PANSS). The PANSS comprises the positive symptoms, negative 
symptoms, general psychopathology, and PANSS total score (Kay et al., 1987). To 
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ensure consistent and reliable ratings, the four psychiatrists simultaneously attended a 
training session for standardizing their use of the PANSS prior to the start of the study. 
Thereafter, they maintained an intra-class correlation coefficient of greater than 0.84 on 
the PANSS at repeated assessments throughout the study. 
 
Cognitive tests  
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), 
used to measure cognitive function, was individually administered by trained 
investigators and supervised by a research psychiatrist (Duff et al., 2008). It consisted of 
12 subtests used to calculate five age-adjusted index scores and a total score (Randolph 
et al., 1998). Test indices were: immediate memory (composed of list learning and story 
memory tasks); visuospatial/constructional (composed of figure copy and line 
orientation tasks); language (composed of picture naming and semantic fluency tasks); 
attention (composed of digit span and coding tasks); and delayed memory (composed of 
list recall, story recall, figure recall, and list recognition tasks). Our group has 
previously translated RBANS into Chinese and its clinical validity and test-retest 
reliability have already been established among controls and schizophrenia patients 
(Zhang et al., 2009). To ensure consistent and reliable ratings, the two clinical 
psychiatrists simultaneously attended a training session to standardize their use of the 
RBANS prior to the study. Thereafter, they maintained an intra-class correlation 
coefficient of 0.92 on the RBANS at repeated assessments throughout the study. 
 
Statistical analysis  
Group comparisons on demographic and clinical variables used Chi squared or Fisher 
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exact tests for categorical variables and analysis of variance (ANOVA) for continuous 
variables. Post-hoc comparisons between subgroups were made using the Tukey’s 
honestly significant difference (HSD) procedure. For the RBANS comparisons, we also 
included age, gender, education, smoking, dose and duration of APDs treatment, and 
anti-Parkinsonian drugs as covariates in the multivariate analyses of covariance 
(MANCOVA). Multiple regression models were used to quantify the amount of 
variance in cognitive functioning explained by the psychopathological variables after 
controlling for several potential confounders, such as gender, age, education, and 
clinical variables. All statistical analyses and database manipulations were performed 
with SPSS version 18.0 (SPSS Inc., USA). Data were presented as mean±SD. All p-
values were two-tailed at the significant level of p<0.05. 
 
Results 
Demographic and clinical information 
Table 1 shows no significant differences among the four examined groups in gender, 
age, education, body mass index (BMI), smoking, and incidence of diabetes (all 
p>0.05). Patients taking clozapine had significantly higher triglyceride levels than 
risperidone and typical APDs (p<0.01). Moreover, patients taking clozapine had 
significantly lower high density lipoprotein than typical APDs (p<0.01). There were no 
significant differences among patients taking clozapine, risperidone, and typical APDs 
in fasting blood glucose, cholesterol, and low density lipoprotein. Furthermore, there 
were no significant differences in any PANSS scores, duration of illness, and APD dose 
(chlorpromazine CPZ equivalents). However, patients taking clozapine showed 
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significantly lower anti-Parkinsonian drugs used than risperidone and typical APDs 
(p<0.001) (Table 2).  
Cognitive performance in patients with chronic schizophrenia on long-term 
treatment with clozapine, risperidone, and typical APDs 
RBANS cognitive index scores for all subjects are summarized in Table 3. After 
controlling the age, education, gender, and smoking, the multivariate analysis of 
covariance revealed that all patients had significantly lower cognitive scores than 
healthy controls in almost all of the total and subscores of RBANS (all p<0.001), except 
for the visuospatial/constructional index. Furthermore, five subscores of RBANS were 
compared among clozapine, risperidone and typical antipsychotic treatment groups after 
adjustment for demographic data, clinical symptoms, antipsychotic drug dose and 
antiparkinsonian drugs. Immediate memory score showed 7.5% decrease in individual 
taking clozapine (58.3±16.6) than typical APDs (62.7±16.8) (p<0.01). Delay memory 
score were 7.1% decrease in individual taking clozapine (66.2±19.7) than typical APDs 
(70.9±20.4) (p<0.01). Language score indicated 8.4% decrease in individual taking 
clozapine (84.5±15.6) than risperdone (78.6±17.4) (p<0.01). Also, individuals taking 
risperidone showed a decreased trend than typical APDs in immediate (p=0.071) and 
delayed memory (p=0.051).  
 
Associations of cognitive impairment with clinical variables in patients with 
chronic schizophrenia on long-term treatment with APDs 
The associations of cognitive impairment with clinical psychopathological variables 
were further examined in patients with schizophrenia. Multivariate regression analysis 
showed that the following variables were independently associated with the RBANS 
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total scores: PANSS negative score (beta=-0.37, t=-6.08, p<0.001); PANSS general 
symptom score (beta=0.13, t=2.2, p<0.05); education (beta=0.15, t=3.03, p<0.01); and 
gender (beta=0.14, t=-2.64, p<0.01). These factors together predicted 16.4% of the 
variance of the RBANS total scores.   
 
Furthermore, the subscores of RBANS were analysed separately to assess the effects of 
the clinical characteristics associated with cognitive impairment. Multivariate regression 
analyses showed that the following variables were independently associated with: (1) 
immediate memory: PANSS negative score (beta=-0.23, t=-4.4, p<0.001), education 
(beta=0.11, t=2.17, p<0.05), age (beta=-018, t=-3.3, p<0.001), gender (beta=0.17, 
t=3.30, p<0.001), and types of APDs (beta=0.18, t=3.60, p<0.001); (2) delayed 
memory: PANSS negative score (beta=-0.27, t=-5.14, p<0.001), gender (beta=0.14, 
t=2.67, p<0.01), education (beta=0.11, t=2.09, p<0.05), and types of APDs (beta=0.14, 
t=2.76, p<0.01); and (3) language: PANSS negative score (beta=-0.34, t=-6.67, 
p<0.001), and education (beta=0.15, t=3.00, p<0.01).  
Discussion 
This study found that all patients showed significant cognitive deficits compared to 
healthy controls in almost all examined cognitive domains, except for the 
visuospatial/constructional index. In particular, individuals taking clozapine showed 
worse immediate and delayed memory than typical APDs, and better language 
performance than risperidone.  
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Cognitive deficits were significantly different for patients with chronic schizophrenia 
during long-term treatment with clozapine, risperidone, or typical APDs. These results 
are supported by other studies (Beninger et al., 2010; Hill et al., 2010; Terry and 
Mahadik, 2007). Though this study was cross-sectional design, it was random and 
therefore might provide robust evidence that APDs may influence cognition in patients 
with chronic schizophrenia on long-term medication. Therefore, more research is 
required to investigate the pharmacological effects of APDs on cognition. 
 
Interestingly, individuals taking clozapine showed 7.5% and 7.1% decrease in 
immediate and delayed memory than typical APDs in patients with chronic 
schizophrenia during long-term medication. Moreover, multivariate regression analysis 
showed that immediate memory and delayed memory were modestly correlated with the 
types of APDs. These results support that clozapine might have worse effects than 
typical APDs on immediate and delayed memory for patients with chronic 
schizophrenia during long-term medication, which is supported by human and animal 
studies (Addy and Levin, 2002; Goldberg et al., 1993; Pocivavsek et al., 2006). 
Currently, we cannot provide a reasonable explanation for these results. However, some 
studies have shown that the inherent anticholinergic properties of some APDs may be 
involved in memory impairment during long-term medication in patients with 
schizophrenia (Minzenberg et al., 2004; Terry and Mahadik, 2007; Thornton et al., 
2006). Moreover, one study suggested that decreased activity in the central cholinergic 
system was involved in the pathophysiology of schizophrenia and cognitive deficits 
(Perry and Perry, 1995). Increasing the activity of the central cholinergic system is 
related to the pharmacotherapy of schizophrenia and may have beneficial effects in 
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improving memory-related cognitive deficits (Bymaster et al., 2003; Simosky et al., 
2003). Furthermore, one study found that low doses of muscarinic antagonists such as 
scopolamine and atropine can lead to inattention and memory impairment (Perry and 
Perry, 1995). Other studies found that cognition such as immediate and working 
memory may be significantly improved after withdrawal of anticholinergic drugs in 
patients with schizophrenia (Mori et al., 2002; Desmarais et al.. 2012). Clozapine has a 
high affinity with the muscarinic M1-5 receptors (Bymaster et al., 2003), and appears to 
function predominantly as an antagonist at the muscarinic M1 and M4 receptors 
(Bymaster et al., 2003). Taken together, these studies show that the stronger inherent 
anticholinergic properties of clozapine rather than typical APDs may at least partly 
contribute to worsened immediate and delayed memory for patients with chronic 
schizophrenia during long-term medication. In addition, animal studies have shown that 
clozapine inhibits nicotine binding at the nicotinic α7 acetylcholine receptors and 
inhibits downstream catecholamine secretion (Park et al., 2001). This inhibition of the 
nicotinic acetylcholine receptors by clozapine and its downstream effects could lead to 
memory impairment (Park et al., 2001), suggesting that the potent anticholinergic 
properties of clozapine on the nicotinic pathway may also have a role in immediate and 
delayed memory impairment in patients with schizophrenia during long-term 
medication. Finally, compared with typical APD treatments, patients taking clozapine 
showed significantly increased triglyceride levels and decreased high density 
lipoprotein (Table 1), which may also lead to worsened immediate and delayed memory 
for individuals taking clozapine than typical APDs in patients with schizophrenia 
(Perlmuter et al., 1988; Umegaki et al., 2014). 
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Another finding from this study is that individuals taking clozapine showed 8.4% 
improvement in language performance than risperidone in patients with schizophrenia 
during long-term medication. This result is supported by other studies (Meltzer and 
McGurk, 1999; Woodward et al., 2005). This study measured cognitive function in the 
language domain using picture naming and semantic fluency tasks. Importantly, 
semantic fluency tasks are one of an important components of neuropsychological 
screenings for executive functioning and processing speed, which are significantly 
impaired cognitive domains in patients with schizophrenia (Gleissner and Elger, 2001). 
Therefore, this study implies that clozapine may be more effective than risperidone in 
improving executive functioning and processing speed in patients with schizophrenia. 
The fact that individuals taking clozapine showed better language than risperidone 
cannot be explained currently. We hypothesize that as clozapine has a significantly 
lower affinity with the D2 receptor than risperidone, it may result in fewer effects of the 
D2 antagonist in the fronto-striatal system (DeLeon et al., 2004). However, as this is a 
hypothesis, it is important to investigate the effects of the two antipsychotic drugs on 
the D2 receptors with in vivo studies in the frontal cortex and hippocampal brain regions 
related to language, executive function, and processing speed (Gleissner and Elger, 
2001). This may be helpful in elucidating the pharmacological effects which causes 
individuals taking clozapine to have better language than risperidone. It is important to 
point out that risperidone at 6 mg per day is the lowest dose, which produces substantial 
changes to negative symptoms, but does not increase extrapyramidal symptoms (EPS) 
(Schooler, 1994). Respirodone at dose above 6mg per day have been reported to 
increase EPS, which may affect cognition in patients with schizophrenia (Suzuki, et al., 
2014). Therefore, different doses of risperidone could vary in the effect on cognition in 
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patients with schizophrenia. The dose for risperidone used in this study was almost all 
less than 6mg per day for patients with schizophrenia. The cognitive effects of 
risperidone at dose above 6 mg per day warrant further investigation. 
    
It is worthy of noting that a number of studies have reported that clozapine has 
significant advantage than risperidone and typical antipsychotics for the improvement 
of negative symptoms (McEvoy, et al., 2006; Lewis, et al., 2006). However, this study 
only showed a trend of improvement for negative symptoms on clozapine than 
risperidone and typical antipsychotics treatments. We could not rule out that the 
potential bias of prescribers for clozapine group in wishing to treat the negative 
symptoms, which might have affected the results. Also, it is possible that the clozapine 
group could be more treatment resistant because of prescribing bias. This limitation 
should be remedied in the future investigation. 
 
This study has some limitations. Firstly, the findings should be regarded as preliminary 
due to the cross-sectional study design in our patients with chronic schizophrenia. 
Secondly, typical APDs were not classified further due to our limited sample sizes, so 
we could not compare the effects of each typical APD on cognitive function with the 
effects of clozapine or risperidone. Thirdly, since this research is a phenomenological 
study, we cannot explain the real pharmacological effects of these APDs. Fourthly, we 
cannot completely rule out the impacts of anticholinergic drug on cognition among 
these examined groups, despite the appropriate management of the statistical analysis 
controlling for this variable. Fifthly, the dosages of antipsychotic drugs used and the co-
medication antiparkinsonian used were not controlled and were chosen by the treating 
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physician based on individual clinical preferences. We cannot rule out the impacts of 
individual clinical preferences for this study. 
 
In conclusion, during long-term APDs medication, patients with chronic schizophrenia 
showed significant cognitive deficits than healthy controls in almost all of the examined 
cognitive domains, except for the visuospatial/constructional index. Individuals taking 
clozapine showed worse immediate and delayed memory than typical APDs, but 
improved language compared with risperidone. An improved understanding of the 
differential effects of APDs on cognition would facilitate optimal treatment strategies to 
maintain or improve cognitive function in patients with schizophrenia and provide an 
important guide for psychiatrists and health carers to treat and care for these patients.  
17 
 
 
Acknowledgments 
This study was funded by grants from the National Health and Medical Research 
Council of Australia (MH635245), The Stanley Medical Research Institute (03T-459 
and 05T-726). These sources had no further role in the study design; the collection, 
analysis, and interpretation of data; the writing of the report; or the decision to submit 
the paper for publication. We would also like to thank Ms Linda Cohen for her editorial 
assistance. 
 
Conflicts of interest 
The authors have no conflicts of interest to be disclosed. 
18 
 
 
References 
Addy N, Levin ED (2002). Nicotine interactions with haloperidol, clozapine and 
risperidone and working memory function in rats. Neuropsychopharmacology 
27: 534-541. 
Beninger RJ, Baker TW, Florczynski MM, Banasikowski TJ (2010). Regional 
differences in the action of antipsychotic drugs: implications for cognitive 
effects in schizophrenic patients. Neurotox Res 18: 229-243.  
Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and long-term 
effect of clozapine treatment on neuropsychological test performance. Biol 
Psychiatry 36: 717-725. 
Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003). 
Muscarinic mechanisms of antipsychotic atypicality. Prog 
Neuropsychopharmacol Biol Psychiatry 27: 1125-1143. 
Daban C, Amado I, Bourdel MC, Loo H, Olie JP, Poirier MF, et al. (2005). Cognitive 
dysfunctions in medicated and unmedicated patients with recent-onset 
schizophrenia. J Psychiatr Res 39: 391-398. 
DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: a comprehensive review of its 
pharmacology, clinical efficacy, and tolerability. Clin Ther 26: 649-666. 
Desmarais JE, Beauclair L, Margolese HC (2012). Anticholinergics in the era of 
atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 
26: 1167-1174. 
Duff K, Humphreys Clark JD, O'Bryant SE, Mold JW, Schiffer RB, Sutker PB (2008). 
Utility of the RBANS in detecting cognitive impairment associated with 
19 
 
 
Alzheimer's disease: sensitivity, specificity, and positive and negative predictive 
powers. Arch Clin Neuropsychol 23: 603-612  
Flanagan RJ (2008). Side effects of clozapine and some other psychoactive drugs. Curr 
Drug Saf 3: 115-122. 
Gleissner U, Elger CE (2001). The hippocampal contribution to verbal fluency in 
patients with temporal lobe epilepsy. Cortex 37: 55-63. 
Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. (1993). 
The effect of clozapine on cognition and psychiatric symptoms in patients with 
schizophrenia. Br J Psychiatry 162: 43-48. 
Hill SK, Bishop JR, Palumbo D, Sweeney JA (2010). Effect of second-generation 
antipsychotics on cognition: current issues and future challenges. Expert Rev 
Neurother 10: 43-57. 
Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al. (1996). 
The effects of clozapine on symptom reduction, neurocognitive function, and 
clinical management in treatment-refractory state hospital schizophrenic 
inpatients. Neuropsychopharmacology 15: 361-269. 
Houthoofd SAMK, Morrens M, Sabbe BGC (2008). Cognitive and psychomotor effects 
of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 30: 1565-
1589. 
Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 Receptor 
explain the action of atypical antipsychotics?: a new hypothesis. Am J 
Psychiatry 158: 360-369. 
Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull 13: 261-276. 
20 
 
 
Keefe RSE, Harvey PD (2012). Cognitive impairment in schizophrenia. Handb Exp 
Pharmacol: 11-37 
Keefe RSE, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, et al. (2006). One-
year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, 
and haloperidol in schizophrenia. Schizophr Res 81: 1-15. 
Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. (2006).                
Randomized controlled trial of effect of prescription of clozapine versus other 
second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 
32: 715-723. 
Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, et al. (1998). 
Clinical and neurocognitive effects of clozapine and risperidone in treatment-
refractory schizophrenic patients: a prospective study. J Clin Psychiatry 59: 521-
527. 
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.   
(2006). Effectiveness of clozapine versus olanzapine, quetiapine, and 
risperidone in patients with chronic schizophrenia who did not respond to prior 
atypical antipsychotic treatment. Am J Psychiatry163 (4):600-610. 
Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine 
on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.  
Minzenberg MJ, Poole JH, Benton C, Vinogradov S (2004). Association of 
anticholinergic load with impairment of complex attention and memory in 
schizophrenia. Am J Psychiatry 161: 116-124 
Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S (2002). Effects of 
anticholinergic drug withdrawal on memory, regional cerebral blood flow and 
21 
 
 
extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 35: 
6-11. 
Nasrallah H (2003). A review of the effect of atypical antipsychotics on weight. 
Psychoneuroendocrinology 28 Suppl 1: 83-96. 
Park T, Bae S, Choi S, Kang B, Kim K (2001). Inhibition of nicotinic acetylcholine 
receptors and calcium channels by clozapine in bovine adrenal chromaffin cells. 
Biochem Pharmacol 61: 1011-1019 
Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M (1988). 
Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J 
Diabet Complications 2: 210-213. 
Perry EK, Perry RH (1995). Acetylcholine and hallucinations: disease-related compared 
to drug-induced alterations in human consciousness. Brain Cogn 28: 240-258.  
Pocivavsek A, Icenogle L, Levin ED (2006). Ventral hippocampal alpha7 and 
alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in 
female rats. Psychopharmacology 188: 597-604. 
Randolph C, Tierney MC, Mohr E, Chase TN (1998). The Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS): preliminary clinical 
validity. Journal of Clinical & Experimental Neuropsychology: J Int 
Neuropsychol Soc 20: 310-319. 
Sharma T, Hughes C, Soni W, Kumari V (2003). Cognitive effects of olanzapine and 
clozapine treatment in chronic schizophrenia. Psychopharmacology 169: 398-
403. 
Schooler NR (1994). Negative symptoms in schizophrenia: Assessment of the effect of 
risperidone. J Clin Psychiatry 55:22–28. 
22 
 
 
Sidlova M, Prasko J, Jelenova D, Kovacsova A, Latalova K, Sigmundova Z, et al. 
(2011). The quality of life of patients suffering from schizophrenia--a 
comparison with healthy controls. Biomed Pap Med Fac Univ Palacky Olomouc 
Czech Repub 155: 173-180. 
Simosky JK, Stevens KE, Adler LE, Freedman R (2003). Clozapine improves deficient 
inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic 
mechanism. Psychopharmacology 165: 386-396. 
Stip E, Lussier I (1996). The effect of risperidone on cognition in patients with 
schizophrenia. Can J Psychiatry 41: S35-40. 
Suzuki H, Gen K, Inoue Y, Hibino H, Mikami A, Matsumoto H, et al. (2014). The 
influence of switching from risperidone to paliperidone on the extrapyramidal 
symptoms and cognitive function in elderly patients with schizophrenia: a 
preliminary open-label trial. Int J Psychiatry Clin Pract 18(1): 58-62. 
Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. (2013). 
Effects of risperidone and olanzapine dose reduction on cognitive function in 
stable patients with schizophrenia: an open-label, randomized, controlled, pilot 
study. Schizophr Bull 39: 993-998. 
Terry AV, Jr., Mahadik SP (2007). Time-dependent cognitive deficits associated with 
first and second generation antipsychotics: cholinergic dysregulation as a 
potential mechanism. J Pharmacol Exp Ther 320: 961-968. 
Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W (2006). The impact of 
atypical antipsychotic medications on long-term memory dysfunction in 
schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 20: 
335-346. 
23 
 
 
Tomida K, Takahashi N, Saito S, Maeno N, Iwamoto K, Yoshida K, et al. (2010). 
Relationship of psychopathological symptoms and cognitive function to 
subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin 
Neurosci 64: 62-69. 
Umegaki H, Kawamura T, Umemura T, Kawano N (2014). Factors associated with 
cognitive decline in older adults with type 2 diabetes mellitus during a 6-year 
observation. Geriatr Gerontol Int. In press.  
Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000). Do 
specific neurocognitive deficits predict specific domains of community function 
in schizophrenia? J Nerv Ment Dis 188: 518-524. 
Vyas NS, Patel NH, Puri BK (2011). Neurobiology and phenotypic expression in early 
onset schizophrenia. Early Interv Psychiatry 5: 3-14. 
Westerink BHC (2002). Can antipsychotic drugs be classified by their effects on a 
particular group of dopamine neurons in the brain? Eur J Pharmacol 455: 1-18. 
Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical 
antipsychotics. J Clin Psychiatry 64: 663-667. 
Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of 
neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone 
in schizophrenia. Int J Neuropsychopharmacol 8: 457-472. 
Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, Shi C, et al. (2009). Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS) as a 
Screening Test in Chinese: Reliability and Validity. Chinese Mental Health 
Journal 28: 865-869. 
 
Table 1 Demographic and clinical information of healthy controls, clozapine, risperidone and typical antipsychotics 
  Healthy controls Clozapine Risperidone Typical antipsychotics F or X
2
 p 
  (n=159) (n=215) (n=91) (n=112)   
Gender (M/F) 132/27 182/33 79/12 95/17 1.6 0.143 
Age (years) 49.1±9.3 48.6±9.4 49.5±9.6 50.3±8.0 1.4 0.245 
Education (years) 9.4±3.1 9.4±4.3 9.3±2.0 8.9±2.0 0.7 0.587 
BMI (kg/m
2
) 25.9±3.9 24.9±3.8 24.4±3.5 24.3±4.6 1.8 0.114 
Smoking (yes/no) 117/42 147/68 59/32 82/30 4.9 0.089 
Diabetes (yes/no) NA 34/181 9/82 21/91 2.7 0.512 
Fast glucose (mmol/l) NA 5.3±1.1 5.0±0.6 5.1±0.7 1.6 0.131 
Cholesterol (mmol/l) NA 4.4±1.0 4.2±0.9 4.5±1.0 1.8 0.154 
Triglyceride (mmol/l) NA 2.0±1.2
**
 1.4±0.8 1.6±1.0 9.5 0.000 
High density lipoprotein (mmol/l) NA 1.2±0.3
##
 1.3±0.3 1.4±0.7 7.1 0.001 
Low density lipoprotein (mmol/l) NA 2.6±0.7 2.5±0.5 2.8±0.6 2.3 0.289 
Mean±SD. 
*
indicates the comparison between clozapine and risperidone or typical antipsychotics:
 **
p<0.01.
 #
indicates the comparison 
between clozapine and typical antipsychotics: 
##
p<0.01.  
 
Table-1
Table 2 Characteristics of patients with chronic schizophrenia on long-term treatment with clozapine, risperidone and 
typical antipsychotics 
  Clozapine Risperidone Typical antipsychotics F or X
2
 p 
  (n=215) (n=91) (n=112)   
Duration of illness (years) 25.3±9.6 26.1±9.6 26.5±8.8 0.675 0.510 
Antipsychotic dose (CPZ equivalents) 428.3±142.9 419.4±116.1 409.2±184.1 0.994 0.372 
Score on positive symptom scale 11.6±4.8 12.3±5.6 11.2±4.7 1.321 0.268 
Score on negative symptom scale 21.3±7.0 22.9±7.9 22.8±7.4 2.370 0.095 
Score on general psychopathology scale 25.0±5,8 26.0±5.9 25.4±5.1 0.964 0.382 
Total PANSS score 57.8±14.4 61.1±15.2 59.5±13.0 1.851 0.158 
Antiparkinsonian drugs  (trihexyphenidyl) (yes/no) 18/197
***
 43/48 60/52 100.3 0.000 
Mean±SD. 
*
indicates the comparison between clozapine and risperidone or typical antipsychotics: 
***
p<0.001. 
CPZ=chlorpromazine.  
 
Table-2
 
   
Table 3 The levels of cognitive function in healthy controls, clozapine, risperidone and typical antipsychotics 
Cognitive index Healthy controls Clozapine Risperidone Typical antipsychotics Main analyses 
  (n=159) (n=215) (n=91) (n=112) F(p value) 
Immediate memory 74.9±16.9 58.3±16.6***
++
 59.5±17.6*** 62.7±16.8*** 12.4(0.000) 
Visuospatial/construction 81.0±14.4 80.5±18.3 78.4±18.7 79.2±19.0 1.1(0.272) 
Language 94.6±11.3 84.5±15.6***
##
 78.6±17.4*** 81.8±13.8*** 13.4(0.000) 
Attention 86.7±17.4 73.1±16.1*** 73.1±20.5*** 74.3±17.7*** 4.3(0.005) 
Delayed memory 87.5±13.9 66.2±19.7***
++
 67.1±19.5*** 70.9±20.4*** 24.5(0.000) 
Total RBANS scores 80.3±13.9 66.1±14.7*** 65.5±16.5*** 66.7±15.8*** 12.1(0.000) 
Mean±SD. *indicates the comparison between healthy controls with clozapine or risperidone or typical antipsychotics: 
 ***p<0.001.
 +
indicates the comparison between clozapine and typical antipsychotics: 
++
p<0.01. 
#
indicates the comparison 
between clozapine and risperidone: 
##
p<0.01. 
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